From Brookfield, Connecticut, USA:
What is the best insulin for an eight-year-old child? Our diabetes specialist prescribed Toujeo, which looks like has not been tested on people under 18. Furthermore, the Sanofi site specifies that Toujeo should not be used in children. So, what are the potential consequences of continuing to use Toujeo? What is a better brand/type of insulin to switch to for long-lasting (morning) injections?
Toujeo and Tresiba are newer basal insulins that look like they produce less hypoglycemia, especially overnight hypoglycemia, work a bit longer and smoother so are replacing former basal insulins (Lantus, Levemir) used in MDI (multi-dose insulin) regimens with meal-time (prandial) Humalog, Novolog or Apidra. Basaglar, a "bio-similar" to Lantus glargine also looks like it produces less hypoglycemia and has fewer peaks than Lantus so similarly is being used as a Lantus replacement by many diabetologists for adults as well as children and adolescents. Initial studies show all of these to be safe and with similar benefits and side effects in kids as well as adults. Toujeo is less likely to be used in kids unless there is significant obesity and insulin resistance with very high basal dose requirements because it is a more concentrated form of basal insulin. So, basaglar and Tresiba are most likely to be used in MDI basal insulin regimens.
Original posting 25 Jul 2018
Posted to Insulin
|Return to the Top of This Page|
Last Updated: Wednesday July 25, 2018 14:34:27
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.